8. Nabi Biopharmaceuticals (NABI) develops vaccines for nicotine addiction and infectious diseases. Its second-quarter loss narrowed 41% to $3.4 million, or 8 cents a share, as revenue turned positive. Nabi has $104 million of cash and no debt. Its stock sells for a forward earnings multiple of 13, a book value multiple of 3.3, a sales multiple of 7.3 and a cash flow multiple of 4 -- 62%, 38%, 93% and 78% discounts to peer averages. Just two analysts follow Nabi. Both advocate purchasing its shares. A median target of $11 implies a one-year gain of 122%.
Bullish Scenario: C.K. Cooper forecasts that Nabi's shares will appreciate 153% to $12.50.